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Abstract
STING is an endoplasmic reticulum (ER) signaling adaptor that is essential for the type I 
Interferon response to DNA pathogens. Aberrant activation of STING is linked to the pathology of 
autoimmune and autoinflammatory diseases. The rate-limiting step for the activation of STING is 
its translocation from the ER to the ER–Golgi intermediate compartment. Here we found that 
deficiency in the Ca2+ sensor STIM1 caused spontaneous activation of STING and enhanced 
expression of type I interferons under resting conditions in mice and a patient suffering from 
combined immunodeficiency. Mechanistically, STIM1 associated with STING to retain it in the 
ER membrane, and co-expression of full-length or a STING-interacting fragment of STIM1 
suppressed the function of dominant STING mutants that cause autoinflammatory diseases. 
Furthermore, deficiency in STIM1 strongly enhanced the expression of type I interferons after 
viral infection and prevented the lethality of infection with a DNA virus in vivo. This work 
delineates a STIM1–STING circuit that maintains the resting state of the STING pathway.
The endoplasmic reticulum (ER) provides a structural platform for activation of the type I 
interferon (IFN) response. Stimulator of interferon genes (STING), a key signaling adaptor 
protein for DNA-sensing pathways localizes to the ER membrane in the resting state1, 2, 3. 
After activation by cytosolic DNAs, it translocates into the ER-Golgi intermediate 
compartment (ERGIC) to recruit TANK-binding kinase 1 (TBK1) and interferon regulatory 
factor 3 (IRF3). IRF3, upon phosphorylation by TBK1, homo-dimerizes and translocates 
into the nucleus to induce transcription of type I IFNs4, 5, 6, 7. Beside an essential role in 
protecting the host against DNA pathogens, STING is also involved in the pathogenesis of 
autoinflammation caused by self-DNAs in murine models8, 9. Accordingly, STING has been 
implicated in the pathogenesis of Aicardi–Goutieres syndrome (AGS), systemic lupus 
erythematosus (SLE) and other type I Interferonopathies10. Furthermore, mutations in 
STING have been uncovered in patients with STING-associated vasculopathy with onset in 
infancy (SAVI) and lupus-like symptoms11, 12, 13. The STING variants found in SAVI 
patients are constitutively active and localize to the ERGIC without the STING ligand, 
cyclic dinucleotides (CDNs), suggesting that they may escape a mechanism that potentially 
maintains the ER localization of STING14. Since CDNs can be generated by cytosolic self-
DNAs derived from mitochondrial damage or genomic instability, and the binding affinity of 
STING for CDNs is high (∼5 nM for 2’,3’ cyclic guanosine monophosphate-adenosine 
monophosphate [2’,3’-cGAMP])15, active inhibitory mechanisms are necessary to tightly 
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control its activation. However, little is known about how the resting state of STING is 
maintained.
High Ca2+ concentration in the ER ([Ca2+]ER) is essential for its normal function. At the 
same time, diverse receptors elevate cytoplasmic [Ca2+] by depleting ER Ca2+ stores 
through a mechanism called store-operated Ca2+ entry (SOCE). Stromal interaction 
molecule 1 (STIM1), an EF-hand-containing Ca2+-binding protein localizes throughout the 
ER when [Ca2+]ER is high, but after depletion of the ER Ca2+ stores, it translocates into 
junctional areas between the ER and plasma membrane, interacts with the pore subunit of 
store-operated Ca2+ (SOC) channels; Orai1, and induces Ca2+ entry16. The essential role of 
STIM1 in effector function of adaptive immune cells including T and B cells has been well 
established17, 18, 19. Mutations in STIM1 cause severe combined immune deficiency (SCID) 
in humans20. Paradoxically, these patients also suffer from lymphoproliferative and 
autoimmune complications. Although for some forms of SCID, the mechanisms behind 
these complications have been worked out; for example, poor development of both central 
and peripheral tolerance21, the underlying causes of inflammatory complications in patients 
harboring mutations in STIM1 are not unknown.
The role of STIM1 in cells of the innate immune system is currently unclear. Here, we 
examined the phenotypes of STIM1-deficient cells and observed that loss of STIM1 induces 
spontaneous activation of the STING-TBK1-IRF3 pathway to activate type I IFN responses 
under sterile conditions in both murine and human cells. Mechanistically, STIM1 directly 
interacted with STING to retain it in an inactive state on the ER membrane. Accordingly, we 
also observed strong resistance to viral infections in STIM1 KO cells and animals. These 
results suggest that STIM1 plays an important role in regulation of the innate immune 
responses in addition to its well-established function in regulation of SOCE in adaptive 
immunity.
Results
STIM1 deficiency induces type I IFN response
To gain insights into possible role of STIM1 in innate immune responses, we checked 
expression of various inflammatory cytokines in Stim1−/− murine embryonic fibroblasts 
(MEFs). Among these, transcripts of Ifnb1 and Il6 as well as interferon-stimulated genes 
(ISGs) were significantly increased in Stim1−/− MEFs compared to those in wild type (WT) 
cells (Fig. 1a). Accordingly, we observed increased amounts of secreted IFN-β protein in 
culture supernatants from Stim1−/− MEFs (Fig. 1b). Due to the well-established role of 
STIM1 in SOCE, it was possible that the increased type I IFN response in Stim1−/− MEFs 
was due to altered intracellular Ca2+ homeostasis. To check this possibility, we compared 
responses between Stim1−/− and Orai1−/− MEFs, both of which show loss of SOCE (Fig. 
1c). However, we did not observe enhanced Ifnb1 expression in Orai1−/− MEFs, indicating 
that block of SOCE or altered intracellular Ca2+ levels do not contribute to increased type I 
IFN response observed in Stim1−/− MEFs.
To verify these observations in primary cells, we examined bone marrow-derived 
macrophages (BMDMs) from WT (Stim1fl/fl) and Stim1fl/flUBC-ERT2-cre mice to induce 
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acute loss of STIM1 expression after tamoxifen treatment (Fig. 1d). Similar to MEFs, we 
observed enhanced expression of Ifnb1 and Il6 transcripts in Stim1−/− BMDMs. Next, we 
examined if this enhanced type I IFN expression phenotype was conserved in human 
macrophages. We generated STIM1−/− THP1 cells by CRISPR/Cas9-mediated genome 
editing using two different gRNA sequences (Supplementary Fig. 1). Similar to murine cells, 
we observed an induction of IFNB1 and IL6 mRNAs and increased IFN-β secretion in 
STIM1−/− THP1 clones (Fig. 1e, f). Moreover, exogenous expression of STIM1 in these 
THP1 clones significantly rescued the phenotype by decreasing type I IFN expression. 
Taken together, these data strongly demonstrate an inhibitory role of STIM1 in type I IFN 
responses. STIM2 is another member of the STIM family that shares 66% amino acid 
sequence similarity with STIM116. Both of them are ER-resident proteins, but they function 
differently in sensing depletion of the ER Ca2+ stores and efficacy to activate Orai channels. 
STIM1 plays a dominant role in activation of SOCE while STIM2 is involved in ER Ca2+ 
homeostasis by sensing subtle changes in [Ca2+]ER2223. To check a possible function of 
STIM2 in regulation of type I IFN responses, we generated two independent STIM2−/− 
THP1 clones. However, neither of the STIM2 KO clones showed elevated expression of 
IFNB1 transcripts (Supplementary Fig. 2). Collectively, these results establish a specific role 
for STIM1 in regulating the resting state of the type I IFN responses in murine and human 
cells.
STING-TBK1-IRF3 pathway links perturbation in STIM1 expression to IFN-β expression
Since both STIM1 and STING, an important regulator for the type I IFN responses, localize 
to the ER membrane, we checked the possibility that STIM1 regulates the function of 
STING. Upon activation of STING via exposure to its ligand 2’,3’-cGAMP, we observed a 
pronounced enhancement of Ifnb1 transcript and protein levels in Stim1−/−, but not Orai1−/− 
MEFs when compared to those in WT MEFs (Fig. 2a). This higher type I IFN response in 
Stim1−/− MEFs was also observed in the presence of cytosolic DNAs after transfection with 
IFN stimulatory DNA (ISD) or poly(dA:dT) that are known to activate the STING pathway, 
but not with poly(I:C), a poor agonist of the STING pathway (Fig. 2b, left). Similarly, we 
observed elevated transcripts of IFNB1 in STIM1−/− THP1 cells transfected with 2’,3’-
cGAMP, but not poly(I:C) (Fig. 2b, right).
To determine whether deficiency of STIM1 induces an increase in type I IFN response 
through the STING-TBK1-IRF3 pathway, we checked for activated IRF3 and TBK1 in WT 
and Stim1−/− MEFs. We examined localization of GFP-IRF3, which was exclusively in the 
cytoplasm in WT MEFs but showed almost equal distribution in the cytoplasm and nuclei in 
Stim1−/− MEFs (Fig. 2c). Biochemically, we detected enhanced homo-dimers of IRF3, in 
Stim1−/− MEFs compared to WT cells under resting conditions (Fig. 2d). Furthermore, we 
found enhanced levels of phosphorylated TBK1 and accordingly increased ratio of p-TBK1 
vs. total TBK1 in Stim1−/− MEFs, BMDMs and STIM1−/− THP1 cells (Fig. 2e). We could 
also detect enhanced dimerization of endogenous STING in Stim1−/− MEFs, which is 
considered an active form of STING (Supplementary Fig. 3a). Likewise, STIM1−/− 
HEK293T cells stably expressing STING also showed enhanced STING dimers and 
multimers (Supplementary Fig. 3b). Next, we examined whether co-deletion of STING in 
STIM1-deficient cells could rescue this enhanced IFN-β expression phenotype. Deletion of 
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both Stim1 and Tmem173 (gene encoding STING) in MEFs (double knockout, DKO) 
dramatically reduced Ifnb1 and Il6 transcripts under resting or cGAMP-treated conditions 
(Fig. 2f). Co-deletion of Tmem173 also rescued increased IFN-β secretion observed in 
Stim1−/− MEFs treated with poly (dA:dT) (Fig. 2g). We observed very similar results using 
THP1 cells. Deletion of both STIM1 and TMEM173 in double knockout (DKO) THP1 cells 
was confirmed by immunoblotting and SOCE measurements (Fig. 2h). DKO THP1 cells 
showed reduced IFNB1 and IL6 mRNA levels, suggesting that the elevated cytokine 
expression in STIM1−/− THP1 cells were derived from increased STING activity. Together, 
these results suggest that the increase in type I IFN responses observed in STIM1-deficient 
cells is mediated by the STING-TBK1-IRF3 pathway, and STIM1 plays a novel role in type 
I IFN signaling via regulating STING function.
Increased type I IFN responses in patient lacking STIM1 expression
Previously, patients showing SCID symptoms and bearing homozygous nonsense mutation 
of STIM1 (E136X) were shown to lack STIM1 expression due to nonsense-mediated mRNA 
decay24. To mimic the phenotype of this patient, we transduced STIM1-deficient cells with 
viral vectors encoding WT and STIM1E136X proteins. We confirmed lack of STIM1 
expression in Stim1−/− MEFs transduced to express STIM1E136X while those with 
STIM1WT showed expression similar to the endogenous protein in WT MEFs (Fig. 3a). 
Importantly, expression of STIM1WT but not STIM1E136X rescued the increased type I IFN 
response in Stim1−/− MEFs (Fig. 3b).
To examine if this was true in STIM1-deficient patients, we harvested primary cells from a 
patient lacking STIM1 expression due to a homozygous STIM1 mutation c.478del, p.
(Ser160fs). The lack of STIM1 expression in patient’s PBMCs was confirmed by 
immunoblotting (Fig. 3c). Patient serum showed enhanced IFN-β, IL-6 and TNF cytokines 
when compared to those observed in three healthy controls (Fig. 3d). Consistently, we also 
observed enhanced expression of ISGs in PBMCs and monocytes from the patient, when 
compared to those in two healthy controls (Fig. 3e). Interestingly, the patient also exhibited 
very mild SAVI-like symptoms – he suffered from desquamation and blistering with skin 
eruptions mainly affecting the palm, soles of the feet and cheeks. He also showed 
pronounced nail dystrophy25. Together, these data confirm that loss of STIM1 in humans 
enhances expression of type I IFN, proinflammatory cytokines and ISGs, similar to murine 
cells.
STIM1 interacts with STING for its retention at the endoplasmic reticulum
The increased type I IFN response together with higher basal activity of the STING-TBK1-
IRF3 pathway in STIM1-deficient cells suggests that STIM1 may be involved in maintaining 
the resting state of the STING pathway. Microscopy analysis showed a strong co-
localization between STIM1 and STING in the ER (Fig. 4a). Hence, we checked if STIM1 
can physically interact with STING to retain it in the ER. When co-expressed in HEK293T 
cells, STIM1 was specifically identified from immunoprecipitates of STING (Fig. 4b). In 
addition, we also validated association between endogenous STIM1 and STING proteins by 
immunoprecipitation (Fig. 4c). This association was specific because another ER-resident 
protein, calnexin could not be detected in immunoprecipitates of STIM1.
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Next, we examined association between STIM1 and STING upon activation of either of the 
proteins. We activated STIM1 by treatment with thapsigargin that depletes the ER Ca2+ 
stores, and activated STING using its ligand, 2’,3’-cGAMP. We observed reduced 
biochemical association between the two proteins by stimulation of either STIM1 or STING 
(Fig. 4d). These data indicate that STING and STIM1 form a protein complex that is 
dissociated due to conformational changes induced by stimulation of either of these proteins. 
Association between STING and STIM1 prompted us to check for a possible role of STING 
in regulating the function of STIM1. We observed reduced SOCE induced by thapsigargin or 
anti-CD3 antibody treatment in HEK293T and Jurkat T cells overexpressing STING 
(Supplementary Fig. 4a, b, c). In addition, we observed enhanced STIM1 translocation to the 
ER-PM junctions in thapsigargin treated STING-deficient (Tmem173−/−) MEFs 
(Supplementary Fig. 4d). Conversely, there was significant enhancement of SOCE in 
TMEM173−/− Jurkat cells (Supplementary Fig. 4e, f). This enhancement was not observed 
in THP1 cells, indicating cell type specificity (Fig. 2h). Taken together, these data show that 
association with STING impacts the function of STIM1 in mediating SOCE.
STING contains four transmembrane (TM) segments in its N terminus that span the ER 
membrane (Fig. 4e)1. STING N-terminal domain (NTD) containing the TM segments plays 
an important role in its ER localization, trafficking and interaction with regulators including 
ZDHHC1, AMFR, TRIM32, and RNF526, 27, 28, 29. Tumor DNA viral proteins, E1A and E7 
also bind to STING NTD to inhibit downstream signaling28. The cytoplasmic region (C-
terminal domain, CTD) of STING contains the dimerization domain (DD), CDN-binding 
region, and the C-terminal tail (CTT) that interacts with TBK1 and IRF3. STIM1 has an N-
terminal ER-luminal region containing the Ca2+-sensing EF-hand motifs and sterile alpha 
motif (SAM) domain that is important for its multimerization after ER Ca2+ depletion. It 
also has a single TM domain that traverses the ER membrane. The cytoplasmic C terminus 
contains multiple functional domains including coiled-coil domains (CC) 1, CC2, CC3, a 
serine/threonine-rich domain (S/T), and a lysine-rich domain (poly-K) that are important for 
binding to the plasma membrane after depletion of ER Ca2+ stores. A fragment containing 
CC2 and CC3 of STIM1 called the CRAC activation domain (CAD) or the STIM1 Orai 
activating region (SOAR) was identified to interact directly with Orai1 subunits to gate 
them16, 29.
To determine their interaction domains, we carried out co-immunoprecipitation using lysates 
of HEK293T cells overexpressing full-length, NTD or CTD of STING together with full-
length STIM1. These results showed NTD of STING as a major STIM1-interacting domain 
while its CTD interacted weakly with STIM1 (Fig. 4f, left panels). To uncover the domain(s) 
of STIM1 involved in interaction with STING, we performed GST pull-down experiments 
by incubating bacterially purified GST-fused fragments of STIM1 with lysates of HEK293T 
cells overexpressing full-length, NTD or CTD of STING. From this analysis, we identified a 
predominant interaction between the N terminus of STIM1 containing the TM segment (a.a. 
1–249) and STING NTD, and a weaker binding of the cytoplasmic fragment predominantly 
containing the S/T-rich region of STIM1 to STING CTD (Fig. 4f, right panels). These data 
suggest that interaction between STIM1 and STING is predominantly mediated by their TM 
domains on the ER membrane with weak additional interactions between their cytoplasmic 
regions.
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STIM1 acts as an ER retention factor to suppress the activity of STING
Ligand binding induces conformational rearrangement and trafficking of STING from the 
ER to the ERGIC and the Golgi apparatus14, 30, 31. Since STIM1 interacted strongly with 
STING NTD, which is crucial for STING localization, we hypothesized that STIM1 may 
control the ER localization of STING. To validate this hypothesis, we examined the 
localization of STING in WT and Stim1−/− MEFs by co-staining with ERGIC marker 
(ERGIC-53/p58). We observed a significant population of Stim1−/− MEFs showing partial 
localization of STING at the ERGIC without any stimulation, and this population increased 
much faster in Stim1−/− MEFs infected with the DNA virus, herpes simplex virus type-1 
(HSV-1) when compared to WT MEFs (Fig. 5a). To check how interaction with STIM1 
influences the function of STING, we monitored the translocation kinetics of STING after 
treatment of WT or Stim1−/− MEFs with 2’,3’-cGAMP and observed faster translocation of 
STING into the ERGIC in Stim1−/− MEFs than in WT cells (Fig. 5b). Together with our 
biochemical analysis, these data suggest that STIM1 physically interacts with STING to 
promote its retention onto the ER membrane.
We checked if overexpression of STIM1 can inhibit the function of STING using Ifnb 
promoter-driven luciferase reporter (IFN-Luc) assays after 2’,3’-cGAMP treatment. In cells 
co-expressing STING and increasing amounts of full length or the N- and C-terminal 
binding fragments of STIM1, we observed a dose-dependent inhibition of luciferase reporter 
expression (Fig. 5c). In support of our biochemical analyses, the N-terminal TM-containing 
fragment of STIM1 (a.a. 1–249) showed a stronger inhibition of luciferase reporter activity 
than the cytoplasmic domain (a.a. 400–600) while STIM1 fragments (a.a. 250–400 and a.a. 
600–685) that do not interact with STING did not affect luciferase activity. Of note, 
expression of full-length STIM1 or its N-terminal fragment (a.a. 1–249) did not influence 
the luciferase activity when stimulated with poly(I:C). These data validate functional 
interaction between STIM1 and STING proteins.
The genetic lesions of patients exhibiting autoinflammatory vasculopathy and autoimmunity 
were mapped to single amino acid substitutions in STING11. These substitution mutations 
changed one of the conserved residues V147, N154, or V155, all of which are localized in or 
around the STING dimerization domain32. In addition, these substitutions lead to 
localization of STING at the ERGIC and constitutive TBK1 and IRF3 activation and 
uncontrolled type I IFN response11, 13. We examined if these disease-associated STING 
mutants retained binding to STIM1. Using immunoprecipitation analysis, we observed 
reduced interaction of the STING SAVI mutants with STIM1 and overexpression of full-
length or N-terminal fragment of STIM1 could suppress Ifnb promoter-driven luciferase 
activity of these mutants. (Supplementary Fig. 5a, b). In support of these data, confocal 
analyses showed a partial block of constitutive ERGIC localization of these mutants in the 
presence of STIM1 (Supplementary Fig. 5c). Collectively, these results confirm the previous 
observations that exit from the ER is an important step for the activation of STING and 
STIM1 can block this trafficking via direct interaction.
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Genetic inhibition of STIM1 expression primes antiviral activity
We sought to determine whether deficiency of STIM1 influences activation of the type I 
IFNs in response to DNA virus infection. To examine this, WT and Stim1−/− MEFs were 
infected with DNA viruses (e.g., HSV-1 and murine γ-herpesvirus, MHV-68). Spontaneous 
induction of IFN-β observed in Stim1−/− MEFs was substantially increased after HSV-1 
infection (Fig. 6a). We also observed a marked reduction in expression of GFP, encoded 
from the viral genome which served as an indicator for viral replication in Stim1−/− MEFs. 
We observed similar results using another DNA virus, MHV-68. Similar to HSV-1 infection, 
MHV-68-infected Stim1−/− MEFs showed much lower expression of the viral genome-
driven GFP, as well as early and late phase viral transcripts (e.g., ORF57 and ORF29, 
respectively), indicative of a lower viral burden (Fig. 6b). In consistence with these data, 
Stim1−/− MEFs showed enhanced phosphorylation of IRF3 upon HSV-1 infection (Fig. 6c). 
We observed similar results in primary cells, where Stim1−/− BMDMs showed enhanced 
expression of Ifnb1 and Il6 mRNAs under resting conditions, as well as after HSV-1 
infection (Fig. 6d). Together, these data show that loss of STIM1 increases resistance to 
DNA virus infections.
Next, we validated these observations in STIM1−/− THP1 macrophages. Similar to data with 
mouse cells, STIM1 deficiency rendered human macrophages resistant to HSV-1, decreasing 
expression of GFP as observed by microscopy and transcript analyses (Fig. 6e). 
Accordingly, we observed enhanced expression of IFNB1 transcripts in STIM1−/− THP1 
cells. Previously, it was shown that anti-viral immunity against HIV infection also relies on 
the cGAS-STING pathway due to the presence of cytosolic DNA generated by reverse-
transcription8, 33. To investigate whether STIM1 deletion imparts resistance to HIV, we 
infected wild type and STIM1−/− THP1 cells with GFP-HIV and observed a dramatic 
reduction of HIV infection in STIM1−/− THP1 cells as judged by frequency of GFP+ cells 
(Fig. 6f). Together, these results suggest that deficiency of STIM1 can prime host response 
against infection with DNA viruses and retroviruses in various murine and human cell types.
Many DNA viruses, including HSV-1 are known to activate Ca2+ signaling for a productive 
infection34. Hence it is possible that resistance to DNA virus infection in Stim1−/− MEFs 
may be due to loss of SOCE. To determine the contribution of SOCE versus enhanced 
STING activity in host resistance to DNA virus infection, we compared responses of 
Stim1−/− and Orai1−/− MEFs to HSV-1 infection. We observed a moderate resistance to 
HSV-1 infection in Orai1−/− MEFs, but in comparison, the resistance to HSV-1 infection was 
approximately 100-fold more pronounced in Stim1−/− cells (Supplementary Fig. 6a). In 
support of the SOCE-independent role of STIM1 in regulation of STING function, we found 
that Ifnb1 mRNA expression was not increased after HSV-1 infection in Orai1−/− cells 
contrary to Stim1−/− cells. Finally, Stim1−/− MEFs when treated with inhibitor of the IFN 
receptor-JAK-STAT pathway, tofacitinib, became susceptible to HSV-1 infection 
(Supplementary Fig. 6b). Together, these results indicate a predominant role of the type I 
IFN pathway in the resistance of STIM1-deficient cells to viral infections.
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Ablation of STIM1 primes type I IFN response in vivo
To gain insight into the importance of STIM1 in host defense against viral infection in vivo, 
we investigated the antiviral immune response in Stim1fl/fl and Stim1fl/flLyz2-cre mice. In 
parallel, to compare the contribution of SOCE in host resistance to viral infections, we 
generated conditionally targeted Orai1 animals (Supplementary Fig. 7a), which were bred 
with Lyz2-cre for two generations. BMDMs differentiated from bone marrows of 
Orai1fl/flLyz2-cre animals showed almost a complete loss of Orai1 transcripts and SOCE 
(Supplementary Fig. 7b, c). Since HSV-1 is a neurotropic virus and the leading cause of 
sporadic viral encephalitis, we investigated the effects of Orai1 and Stim1 deficiency on 
HSV-1-induced lethality and viral loads in the brain. When infected with HSV-1 
intravenously, control (Stim1fl/fl and Orai1fl/fl) as well as Orai1fl/flLyz2-cre animals showed 
susceptibility and died within 6–8 days of infection (Fig. 7a, b). In contrast Stim1fl/flLyz2-
cre mice were completely resistant to HSV-1-induced lethality, and accordingly, recovered 
from loss of body weight. Viral titers in the brains obtained from Stim1fl/flLyz2-cre mice 
were significantly lower than Stim1fl/fl animals (Fig. 7c). Importantly, serum cytokine 
measurements showed elevated levels of serum IFN-β, IL-6 and TNF in uninfected as well 
as HSV-1-infected Stim1fl/flLyz2-cre mice, when compared to littermate controls (Fig. 7d). 
Taken together, our data indicate that genetic deletion of Stim1 but not Orai1 can impart 
protection from HSV-induced encephalitis and lethality, due to pre-activation of the STING-
mediated type I IFN signaling pathway.
Discussion
STING and STIM1 commonly contain transmembrane domain(s) in their N termini and 
predominantly localize to the ER membrane. Co-immunoprecipitation experiments showed 
an association between the two proteins, that was primarily mediated by their N-terminal 
transmembrane domains. We showed that loss of STIM1 renders cells and mice strongly 
resistant to viral infections due to enhanced expression of type I IFNs and pro-inflammatory 
cytokines. Importantly, a patient with a mutation in STIM1 that abrogated STIM1 expression 
also showed elevated cytokines and ISGs. Furthermore, some of the patient’s clinical 
features, principally the skin and nail manifestations resemble that of SAVI patients, 
suggesting that the excessive type I IFNs do have adverse biological manifestation in this 
condition25. Mechanistically, enhanced translocation and dimerization of STING by STIM1 
deficiency suggest that STIM1 may preferentially bind to STING monomers at the ER to 
prevent its spontaneous activation. Conversely, we also found that STING deficiency 
augmented translocation of STIM1 and Ca2+ entry triggered by depletion of ER Ca2+ stores. 
Therefore, our studies suggest that physical and functional association between STIM1 and 
STING is crucial for maintenance of the resting state of both pathways.
We showed that enhanced type I IFN expression in STIM1-deficient cells is not mediated by 
Ca2+ signaling by comparative studies with Orai1-deficient cells and animals. STIM1 
deficiency made cells and mice strongly resistant to HSV-1 infections. Since many viruses 
including HSV-134, require elevated Ca2+ levels for their replication, we determined the 
contribution of the Ca2+-dependent (i.e., decreased SOCE) vs. Ca2+-independent 
mechanisms (i.e., enhanced type I IFN response) involved in anti-viral immunity in STIM1-
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deficient cells using two independent molecular tools, Orai1−/− cells/mice and JAK 
inhibitors. These results suggest that decreased viral burden in STIM1-deficient cells and 
mice is predominantly derived from enhanced type I IFN responses. Whether the same 
principle can be applied to other viruses with various degrees of dependence on Ca2+ 
signaling and activation of the STING pathway needs further studies.
Although much is understood regarding the mechanisms underlying activation of STING 
including ligand binding, trafficking and interaction with downstream effector molecules, 
little is known about regulation of its resting state. Multiple mechanisms underlying STING 
inhibition have been uncovered due to the importance of timely inactivation of the type I 
IFN signaling pathway. NLRX1 and ATG9a have been shown to inhibit STING-TBK1 
interaction26, 27. In addition, K48-linked polyubiquitination by RNF5 and TRIM30a results 
in STING degradation after ligand binding35, 36. All these inhibitory mechanisms target 
STING function after ligand binding and trafficking. However, inhibition of STING 
trafficking by brefeldin A, an inhibitor of ADP ribosylation factor (ARF) GTPases, blocks 
activation of the downstream pathway, suggesting that trafficking of STING is crucial for its 
function14. Consistently, our studies reveal a novel mechanism of regulation of STING 
activity, inhibition of STING trafficking via direct interaction with STIM1. Activity of three 
of the disease-associated STING variants; V147L, N154S, and V155M was suppressed by 
STIM1 in part via blocking their translocation to the ERGIC, demonstrating a therapeutic 
potential of our finding. In summary, our study identifies STIM1 as an “ER retention factor” 
to maintain ER residency and inactive conformation of STING. Further, it suggests that one 
of the primary functions of CDN binding to STING is to disrupt its association with STIM1 
that would allow exit of STING from the ER. Further dissection of the mechanisms 
underlying maintenance of the resting state of STING may inform the design of specific 
therapeutic strategies geared towards enhancement/inhibition of STING activity in the 
context of vaccination and sterile inflammatory diseases (e.g., AGS and SAVI), respectively.
Methods
Chemicals and Antibodies.
Fura 2-AM (F1221) was purchased from ThermoFisher Scientific. Thapsigargin and 
ionomycin were purchased from EMD Millipore. Poly(I:C) (P1530) was purchased from 
Millipore Sigma. Poly(dA:dT) (tlrl-patn) and 2’,3’-cGAMP (tlrl-nacga23) were purchased 
from InvivoGen. Tofacitinib (S500110MG) was purchased from Selleck Chemical LLC. 
Antibodies for detection of STIM1 (5668S), phosphor-IRF3 (29047S), IRF3 (4302S), 
phosphor-TBK1 (5483S), total TBK1 (3504S), STING (13647S), 6xHis tag (12698S), and 
STIM2 (4917S) were purchased from Cell Signaling Technologies. Antibodies for detection 
of FLAG tag (F3040), p58 (ERGIC marker, E1031) and human Orai1 (AB9868) were 
purchased from Millipore Sigma. Antibody for detection of β-actin (sc-47778) was obtained 
from Santa Cruz Biotechnology and antibodies for detection of STIM1 (clone 5A2) and 
GAPDH (GTX100118) from human PBMCs were obtained from Sigma and GeneTex 
respectively.
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Plasmids and cells.
STIM1-YFP plasmid has been described previously37. Human STIM1 cDNA was subcloned 
into a lentiviral vector, FGllF (kind gift from Dr. Dong Sun An, UCLA) with a C-terminal 
FLAG tag and pcDNA 3.1 mychis plasmid. GST-tagged truncated fragments of STIM1 
corresponding to amino acids 1–249 (containing the EF-hand, SAM domain and 
transmembrane segment), 250–400 (containing coiled-coil domains 1 and 2), the CAD 
domain (amino acids 342–448), 400–600 (the serine and threonine-rich region), and 600–
685 (the C-terminal PIP2-interacting domain) have been previously described37. Fragments 
of STING corresponding to the N-terminal TM domain (a.a. 1–154) and C-terminal domain 
(a.a. 149–379), both tagged with a FLAG tag in the C-terminus, were subcloned into 
pMSCV-CITE-eGFP-PGK-Puro vector. Full-length cDNA of human STING and SAVI 
mutants corresponding to V147L, N154S and V155M were subcloned into pEGFPN1 vector 
to generate a C-terminal GFP fusion protein and into pMSCV-CITE-eGFP-PGK-Puro vector 
that encodes a C-terminal FLAG tag using primers described in Supplementary Table 1. 
Oligonucleotides encoding sgRNAs to delete STIM1, STIM2 and STING were subcloned 
into lentiGuide-Puro vector (Addgene, #52963). HEK293T, Vero and Jurkat E6–1 T cell 
lines were obtained from American Type Culture Collection center (ATCC, Manassas, VA). 
WT and Stim1−/− MEFs were generated by breeding Stim1fl/fl mice (Jackson Laboratory, 
stock No. 023350) with CMV-cre mice (Jackson Laboratory, stock No. 006054). MEFs were 
established using standard protocols from E14.5 embryos and retrovirally transduced with 
SV40 large T antigen in a plasmid encoding hygromycin resistance for immortalization. 
Orai1−/− MEFs have been previously described38.
Cell Culture.
MEFs, Vero and HEK293T cells were grown in complete DMEM (Mediatech) 
supplemented with 10% (v/v) fetal bovine serum (Hyclone), 2 mM L-glutamine 
(Mediatech), 10 mM HEPES (Mediatech) and Penicillin/Streptomycin (Mediatech) at 37°C 
and 5% CO2. BMDMs were differentiated from bone marrow cells isolated from femur and 
tibia of 6–8-week-old mice. For preparation of BMDMs, the bone marrow cells were 
cultured in 10% M-CSF-containing conditional medium from HEK293T cells expressing 
recombinant M-CSF (a kind gift from Stephen Smale lab, UCLA) for 4–6 days. BMDMs 
were cultured in the absence of M-CSF for at least 24 hours prior to experimental use. THP1 
and Jurkat T cells were cultured in RPMI (Mediatech) containing 10% fetal bovine serum 
(Hyclone). Cells were infected with indicated MOIs of indicated viruses and harvested in 
TRIzol Reagent for transcript expression analysis. For 2’,3’-cGAMP treatment, MEFs or 
HEK293T cells were treated with or without 1 μM 2’,3’-cGAMP for 30 mins in digitonin 
permeabilization buffer (50 mM HEPES, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM 
sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP, pH 7.0) followed by culture medium for 
indicated times, after which the cells were harvested for transcript analysis or reporter 
assays. MEFs were transfected with 5 μg of interferon stimulatory DNA (ISD39), polydA:dT 
or poly I:C using Lipofectamine 2000 (Thermofisher Scientific). For ELISAs, MEFs were 
treated with cGAMP as described and supernatant harvested after 24 hrs.
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Mice.
Stim1fl/fl animals were purchased from Jackson Laboratory (stock No. 023350) and bred 
with Lyz2-cre animals (Jackson Laboratory, stock No. 004781) for two generations. 
Targeting of murine Orai1 was performed by flanking exon 2 with LoxP sites by 
homologous recombination in AB2.2 (129SvEv) embryonic stem (ES) cells. Exon 2 encodes 
for 201 a.a. out of a total of 304 a.a. of Orai1 protein. G418-resistant clones were screened 
by PCR for homologous recombination at both homology arms. Chimeric mice with floxed 
Orai1 alleles were generated by blastocyst injection of heterozygous Orai1fl/+ ES cell clones. 
Founder Orai1fl/+ mice were bred with Flp-deleter mice (Jackson Laboratory) to remove the 
neomycin resistance gene cassette. Orai1fl/fl mice were backcrossed to C57/BL6/J mice for 
at least 10 generations and then bred with Lyz2-cre mice to generate myeloid-specific 
deletion of Orai1. All mice were maintained in pathogen-free barrier facilities and used in 
accordance with protocols approved by the Institutional Animal Care and Use Committee at 
the UCLA.
Patient.
Sample collection from the patient was performed after obtaining written consent from his 
parents according to the principles of the Declaration of Helsinki and after local ethics 
approval. Detailed clinical evaluation was undertaken in appropriate clinical setting. PBMC 
isolation from healthy control and patient human blood samples was performed by gradient 
separation using Lymphoprep (Stem Cell Technologies). Monocytes were purified from 
PBMCs using a Monocytes separation kit II (# 130-091-153, Miltenyi Biotec). The patient is 
a 4-year-old boy of consanguineous Pakistani background, who initially presented to 
paediatric neurology due to poor mobility. A diagnosis of STIM1 deficiency was made 
following referral to paediatric immunology due to recurrent sinopulmonary infections. The 
patient has typical non-immunological features consistent with STIM1 deficiency including 
amelogenesis imperfecta resulting in complete dental clearance, anhidrosis and muscle 
weakness. Surprisingly, the patient had mild immunodeficiency phenotype, with relatively 
preserved immunological function, including appropriate responses to challenge 
vaccination25.
Virus amplification and concentration.
MHV68-GFP virus was amplified and titrated in NIH3T3 cells using standard protocols. 
HSV-1 KOS strain was used for all in vitro experiments and HSV-1 17+ strain was used for 
in vivo infection experiments. Both the strains were amplified and titrated in Vero cells using 
standard protocols. HSV-1 17+ strain was concentrated for in vivo experiments. VSV-G 
pseudotyped HIV-1NL4–3 strain-GFP reporter virus was amplified and titrated in HEK293T 
cells using standard protocols.
RNA isolation, cDNA synthesis and Real-time quantitative PCR.
Total RNA from cells harvested in TRIzol Reagent (ThermoFisher) was isolated using the 
Direct-zol RNA isolation kit (Zymo Research). RNA quantity and quality were confirmed 
with a NanoDrop ND-1000 spectrophotometer. cDNA was synthesized using 2–3 μg of total 
RNA using oligo(dT) primers and Maxima Reverse Transcriptase (Thermofisher Scientific). 
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Real-time quantitative PCR was performed using iTaq Universal SYBR Green Supermix 
(Bio-Rad) and an iCycler IQ5 system (Bio-Rad) using gene-specific primers described in 
Supplementary Table 1. Threshold cycles (CT) for all the candidate genes were normalized 
to those for 36b4 to obtain ΔCT and further normalized to the values obtained for WT 
samples to obtain ΔΔCT. The specificity of primers was examined by melt-curve analysis 
and agarose gel electrophoresis of PCR products. Total RNA from human patient and 
healthy donors PBMCs and monocytes harvested was isolated using the Total RNA 
purification Kit (Norgen Biotek Corp.). cDNA was synthesized using 1–2 μg of total RNA 
using High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). Real-time 
quantitative PCR was performed using TaqMan Universal PCR Master Mix (ThermoFisher 
Scientific) using FAM-MGB probes for detection of MX1 (Hs00895608_m1), IFI44 
(Hs00951349), IFI44L (Hs00915292_m1), IFI27 (Hs01086370_m1), ISG15 
(Hs00192713_m1), CXCL10 (Hs01124251_g1), RSAD2 (Hs01057264_m1), IFIT1 
(Hs01675197_m1), IFI6 (Hs00242571_m1), OAS1 (Hs00973635_m1), IL6 
(Hs00985639_m1), and HPRT1 (Hs99999909_m1). The relative abundance of each 
transcript was normalized to the expression level of HPRT1 to obtain ΔCT and further 
normalized to the values obtained for healthy controls to obtain ΔΔCT.
Cytokine measurement by ELISA.
ELISA was performed on cell culture supernatants from indicated cells or serum samples 
harvested from mock or HSV-1-infected animals for detection of IFNβ (Biolegend, # 
439407), IL-6 (ThermoFisher, # 88-7064-88) and TNF (ThermoFisher, # 88-7324-88). 
Serum samples obtained from healthy controls or STIM1-deficient human patient were used 
for detection of IFNβ (PBL Assay Science, #41410), IL-6 (ThermoFisher Scientific, # 
88-7066-22) and TNF (ThermoFisher Scientific, # 88-7346-22).
Single-cell Ca2+ imaging, live-cell epifluorescence or TIRF microscopy and confocal 
microscopy.
THP1 and Jurkat T cells were loaded at 1 × 106 cells/ml with 1 μM Fura 2-AM for 40 min at 
25oC and attached to poly-L-lysine–coated coverslips. MEFs or BMDMs were grown 
overnight on coverslips and loaded with 1 μM Fura 2-AM for 40 min at 25oC for imaging. 
Intracellular [Ca2+]i measurements were performed using essentially the same methods as 
previously described40. For live-cell epifluorescence imaging of STING-GFP translocation 
kinetics, MEFs grown on coverslips were perfused with Ringer’s solution containing (in 
mM): 155 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 10 D-glucose, and 5 Na-HEPES (pH 7.4) and 
used for time course imaging. Cells were perfused with digitonin permeabilization buffer (50 
mM HEPES, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM sucrose, 0.2% BSA, 1 mM 
ATP, 0.1 mM GTP, pH 7.0) containing 1 μM 2’,3’-cGAMP for 10 mins and then the medium 
was replaced with Ringer’s solution. For TIRF analysis of STIM1-YFP translocation, MEFs 
were plated onto coverslip bottom dishes in medium and used for experiments. Medium was 
replaced with Ringer’s solution and cells were treated with 1 μM thapsigargin for passive 
depletion of ER Ca2+ stores to monitor STIM1 translocation. TIRF microscopy was 
performed using an Olympus IX2 illumination system mounted on an Olympus IX51 
inverted microscope using previously described methods37. Acquisition and image analysis 
were performed using Slidebook (Intelligent Imaging Innovations, Inc.) software and graphs 
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were plotted using OriginPro8.5 (Originlab). For quantification of TIRF intensity across 
different cells, individual regions of interest were selected and data were analyzed as the 
ratio of fluorescence intensity at each time-point (F) to that at the start of the experiment 
(F0). For confocal analysis, uninfected or HSV-infected MEFs were fixed for 20 mins with 
2.5% PFA at room temperature, permeabilized in buffer containing PBS + 0.2% Triton 
X-100, blocked with same buffer containing 1% BSA and used for staining of ERGIC 
marker and confocal analysis. Confocal laser scanning microscopy was performed using 
Fluoview FV10i Confocal Microscope (Olympus), images were captured with a 60x oil 
objective. Images were processed for enhancement of brightness or contrast using Fluoview 
software.
Generation of STIM1, STIM2 and STING-deficient cells using CRISPR-Cas9 system.
To generate lentiviruses for transduction, HEK293T cells were transfected with plasmid(s) 
encoding sgRNA and packaging vectors (pMD2.G and psPAX2, Addgene) using calcium 
phosphate transfection method. Lentiviruses encoding Cas9 were generated using the same 
technique. Culture supernatants were harvested at 48 and 72 hours post transfection and used 
for infection (50% of Cas9-encoding virus + 50% of sgRNA-encoding virus) of MEFs, 
THP1 or Jurkat T cells together with polybrene (8 µg/ml) using the spin-infection method. 
Cells were selected with puromycin (1 µg/ml) and blasticidin (5 µg/ml) 48 hours post 
infection. The sequences of the sgRNAs are described in Supplementary Table 1.
Immunoprecipitation and immunoblotting.
For immunoprecipitation, cDNA encoding full-length or fragments (a.a. 1–154 and 149–
379) of FLAG-tagged STING and 6xHis-tagged STIM1 was transfected into HEK293T 
cells. Transfected cells (2 × 107) were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 
135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA-630, protease inhibitor mixture, pH 
7.5) and centrifuged at 100,000 x g for 1 hour before preclearing with protein G-Sepharose. 
Lysates were immunoprecipitated with anti-FLAG antibody-conjugated resin for 6 hours. 
Immunoprecipitates were washed five times in lysis buffer and analyzed by immunoblotting. 
For immunoblot analyses, cells were lysed in RIPA buffer (10 mM Tris-Cl, 1% Triton 
X-100, 0.1% SDS, 140 mM NaCl, 1 mM EDTA, 0.1% sodium deoxycholate, and cOmplete 
Protease Inhibitor Cocktail [Sigma-Aldrich], pH 8.0) and centrifuged to remove debris. 
Samples were separated on 8–10% SDS-PAGE. Proteins were transferred to nitrocellulose 
membranes and subsequently analyzed by immunoblotting with relevant antibodies. For 
dithiobis succinimidyl propionate (DSP) crosslinking, MEFs or HEK293T cells were left 
untreated or treated with 0.125, 0.25, 0.5, or 1.0 mM of DSP for 1 hour on ice, followed by 
quenching with 20 mM Tris-Cl, pH 7.5. Cells were lysed in SDS loading dye under non-
reducing conditions (without β-Mercaptoethanol) and separated on 10% SDS-PAGE and 
immunoblotted for detection of indicated proteins. For endogenous immunoprecipitation, 
HEK293 cells were lysed in lysis buffer (same as above) and centrifuged at 100,000 x g for 
1 hour before preclearing with protein G-Sepharose. Lysates were incubated with 2 μg of 
anti-STING antibody (Cell Signaling Technologies) overnight and subsequently with protein 
G-Sepharose for 2 hours. For immunoprecipitation of STING SAVI mutants with 
endogenous STIM1, HEK293T stably expressing FLAG-tagged human STINGWT, 
STINGV147M, STINGN154S or STINGV155M cDNAs were lysed in lysis buffer (same as 
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above), centrifuged at 100,000 x g for 1 hour, pre-cleared and incubated with anti-FLAG 
antibody-conjugated resin overnight in lysis buffer containing 0.1% Igepal CA-630 and 
processed as described above. PBMCs were lysed in NP40 Lysis Buffer (VWR Life 
Science) containing cOmplete Protease Inhibitor Cocktail (Sigma-Aldrich) and centrifuged 
to remove debris. 20 μg of total protein from healthy control or patient samples was 
separated on a 4–12% Bis-Tris Plus Gel (ThermoFisher), transferred to polyvinylidene 
difluoride (PVDF) membrane and subsequently analyzed by immunoblotting with relevant 
antibodies.
Purification of recombinant proteins from E. coli.
Full-length and fragments (a.a. 1–249, 250–400, 324–448, 400–600, and 600–685) of 
STIM1 were subcloned into pGEX4T-1 plasmid. GST fusion protein expressing 
transformants were grown in liquid cultures and induced with isopropyl-1-thio-β-D-
galactopyranoside (IPTG, 0.2 mM) at 18°C overnight. Subsequently, cells were harvested 
and resuspended in lysis buffer (50 mM NaH2PO4, 500 mM NaCl, 10% glycerol, pH 8.0) 
containing protease inhibitors and 0.5% Triton X-100. Lysates were sonicated, centrifuged 
to remove debris and incubated with glutathione sepharose 4B beads for 2 hrs. After 
washing 8 times with lysis buffer, the beads were stored in lysis buffer without Triton X-100 
at −20˚C.
GST pulldown analysis.
cDNA encoding full-length and fragments of STING-FLAG was transfected into HEK293T 
cells. Transfected cells (2 × 107) were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 
135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA-630, protease inhibitor mixture, pH 
7.5) and centrifuged at 100,000 x g for 1 hour before preclearing with protein G-Sepharose. 
Lysates were incubated with 20 µg of GST or GST-tagged fragments of STIM1 for 18 hours 
in binding buffer (0.5% Igepal CA-630, 20 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA, 
10% glycerol, protease inhibitors, pH 7.5). Pulldown samples were washed five times with 
lysis buffer and analyzed by immunoblotting for indicated proteins.
HSV infection in mice.
Age and gender-matched control (Stim1fl/fl or Orai1fl/fl), Stim1fl/flLyz2-cre or 
Orai1fl/flLyz2-cre mice were intravenously injected with 1 × 107 pfu of HSV-1 17+ strain. 
The viability of the infected mice was monitored for 10 days. Mouse serum was collected at 
indicated times after infection for measurement of serum cytokine by ELISA.
Statistical analysis.
Statistical analysis was performed using the Origin2018b software (OriginLab, 
Northampton, MA, USA). Data are presented as mean ± s.e.m. For all dataset, normality and 
homogeneity of variance were evaluated by Shapiro-Wilk test and Levene test respectively, 
to ensure that the assumptions inherent to parametric significance testing were not violated. 
Statistical significance to compare two quantitative groups was evaluated using two-tailed/
unpaired t-test. When multiple groups and/or multiple condition comparisons were 
necessary, one-way or two-way ANOVA was performed followed by a Tukey HSD post-hoc 
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test. Statistical comparison of multiple counts in contingency tables was performed using 
Chi-square test followed by pairwise analysis of differences as post-hoc test. A critical value 
for significance of P < 0.05 was used throughout the study, and statistical thresholds of 0.05, 
0.005 as well as 0.0005 are indicated in the figures by asterisks (see legends for details).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. STIM1 deficiency spontaneously induces type I IFN response in murine and human 
cells.
a, Representative immunoblot showing expression of STIM1 in wild type (WT) and 
Stim1−/− MEFs (left). qPCR analysis of indicated cytokines and ISGs in unstimulated 
indicated MEFs (right). qPCR data show pooled technical replicates from two independent 
experiments (Ifnb1 and Il6) and one representative triplicate from two independent 
experiments (other genes). b, Levels of secreted IFN-β from culture supernatants of 
unstimulated WT or Stim1−/− MEFs. c, Representative traces showing averaged SOCE from 
WT (31 cells), Orai1−/− (30 cells) and Stim1−/− (29 cells) MEFs after passive depletion of 
intracellular Ca2+ stores with 1 μM thapsigargin (TG) in the presence of external solution 
containing 20 mM Ca2+ (left). Bar graph (middle) shows averaged baseline subtracted 
SOCE (± s.e.m.) from four independent experiments. right: qPCR analysis of Ifnb1 mRNA 
in indicated MEFs. d, Representative immunoblot showing expression of STIM1 in BMDMs 
(left). qPCR analysis of Ifnb1 and Il6 mRNA in unstimulated WT and Stim1−/− BMDMs 
(right). e, Immunoblot showing expression of STIM1 in wild type (WT) and STIM1−/− 
THP1 cells generated using two independent sgRNAs (sg#2) and 3 (sg#3). qPCR analysis of 
IFNB1 and IL6 mRNA in unstimulated WT, STIM1−/− THP1 cells and those reconstituted 
for expression of STIM1 (right two panels). f, Secreted IFN-β levels from culture 
supernatants of untreated or PMA-differentiated WT or STIM1−/− THP1 cells. Data show 
representative triplicate from two independent experiments (panels b, e and f) or pooled 
technical replicates from two (c) or three (d) independent experiments. All immunoblot data 
(panels a, d and e) are representative of three independent experiments with similar results. 
Data are shown as mean ± s.e.m. *p < 0.005, and **p < 0.0005 (unpaired/two-tailed t test – 
a, b, d; One-way ANOVA – c; and Two-way ANOVA – e).
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Figure 2. STING-TBK1-IRF3 pathway links loss of STIM1 expression to Ifnb1 transcription.
a, qPCR analysis of Ifnb1 mRNA in indicated MEFs under resting conditions or after 
stimulation with 2’,3’-cGAMP for 2 or 4 h (left). Numbers on top indicate average fold 
change relative to WT MEFs. Secreted IFN-β levels from culture supernatants of indicated 
MEFs after stimulation with 2’,3’-cGAMP (right). Data show pooled technical replicates 
from two independent experiments (qPCR) or one representative triplicate from two 
independent experiments (ELISA) with similar results. b, qPCR analysis of Ifnb1 transcripts 
in indicated MEFs transfected with interferon stimulatory DNA (ISD), poly(dA:dT) or poly 
(I:C) for indicated time (left). qPCR analysis of IFNB1 mRNA from untreated or indicated 
nucleic acid-transfected THP1 cells. c, Representative confocal images showing localization 
of GFP-IRF3 in indicated MEFs. Bar graph below depicts quantification from indicated 
number of cells. Scale bars, 5 μm. d, Representative immunoblot for detection of IRF3 under 
non-reducing conditions in DSP-crosslinked indicated MEFs, (left). Bar graph (right) shows 
densitometry analysis of IRF3 ratio (dimer/monomer) from three independent experiments. 
e, Representative immunoblots showing expression of phospho-TBK1 (P-TBK1), total 
TBK1, and 𝛽-actin from indicated cells. Numbers below indicate normalized fold change in 
ratio of P-TBK1/total TBK1. f, Representative immunoblots showing expression of STIM1 
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and STING in WT, Stim1−/−, or Stim1−/− and Tmem173−/− double knock out (DKO) MEFs 
(left). Expression of Ifnb1 and Il6 transcripts in indicated MEFs under resting conditions 
(left two panels) or 4 h after stimulation with 2’,3’-cGAMP (right two panels). g, Secreted 
IFN-β levels from culture supernatants of indicated MEFs after stimulation with indicated 
nucleic acids. h, Representative immunoblots showing expression of STIM1 and STING in 
WT, STIM1−/−, TMEM173−/− or STIM1−/− and TMEM173−/− double knock out (DKO) 
THP1 cells (left). Representative traces of averaged SOCE from WT (33 cells), STIM1−/−, 
(30 cells), TMEM173−/− (31 cells) and DKO (31 cells) THP1 cells after passive depletion of 
intracellular Ca2+ stores with 1 μM thapsigargin (TG) in the presence of external solution 
containing 2 mM Ca2+ (middle). Bar graph shows averaged baseline subtracted SOCE (± 
s.e.m.) from three independent experiments. Right panels show qPCR analysis of IFNB1 or 
IL6 mRNA in indicated THP1 cells. Data show representative triplicates from two 
independent experiments with similar results (b, d, f, g and h) unless indicated. All 
immunoblots are representative of at least three independent experiments with similar 
results. Data are shown as mean ± s.e.m. *p < 0.05, **p < 0.005, ***p < 0.0005 [Two-way 
ANOVA – a (left panel); unpaired/two-tailed t test – a (right panel), b; Chi-square test – c; 
and One-way ANOVA – d, f, g, h].
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Figure 3. STIM1 deficiency causes enhanced type I IFN response in patient cells.
a, Representative immunoblot showing expression of STIM1 in WT, Stim1−/− MEFs or 
those expressing either WT STIM1 (+STIM1) or STIM1E136X (+E136X) mutant. b, qPCR 
analysis of Ifnb1 and Il6 mRNA in indicated MEFs under resting conditions or 2 h after 
stimulation with 2’,3’-cGAMP. Data show representative triplicate from two independent 
experiments. c, Representative immunoblot showing expression of STIM1 and GAPDH in 
PBMCs isolated from a healthy control (HC) and patient (Pat.). d, Levels of indicated 
cytokines in serum samples from healthy controls (three independent donors) and STIM1-
deficient patient. Data show one representative triplicate from two independent experiments 
(n=9 for three HCs). e, Taqman qPCR analysis of indicated ISGs from peripheral blood 
mononuclear cells (PBMCs, top) or purified monocytes (below) from two independent 
healthy controls and STIM1-deficient patient. Patient data (normalized to those of healthy 
controls) are derived from two independent experiments performed in duplicates. Data are 
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shown as mean ± s.e.m. *p < 0.05, **p < 0.005, ***p < 0.0005 (One-way ANOVA – b; and 
unpaired/two-tailed t test – d, e).
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Figure 4. STIM1 interacts with STING for its retention in the endoplasmic reticulum.
a, Representative confocal microscopy image of STING-GFP and STIM1 in a MEF cell. 
Scale bar, 5 µm, Inset – 1 µm. Pearson’s r = 0.67 ± 0.08 from 9 cells. b, FLAG-
immunoprecipitates (IP) from lysates of HEK293T cells overexpressing FLAG-tagged 
STING and His-tagged STIM1 were immunoblotted for detection of STIM1. Arrow, 
monomeric STING or STIM1; *, STING multimers. c, Immunoprecipitates of endogenous 
STING from HEK293 cells were immunoblotted for detection of indicated proteins. d, 
FLAG-immunoprecipitates (IP) from lysates of HEK293T cells expressing FLAG-tagged 
STING and His-tagged STIM1 with or without treatment with thapsigargin (1 μM, 10 min; 
left) or 2’, 3’-cGAMP (1 μM, 30 min and further incubation in media for 1 h) were 
immunoblotted for detection of the indicated proteins. Bar graphs show densitometry 
analysis of normalized fold changes (mean ± s.e.m.) in STIM1 and STING band intensity 
from three (left) and four (right) independent experiments. e, Schematic showing domain 
structure of STING and STIM1 as indicated in the text. Amino acid residues of STING and 
STIM1 fragments used in this study are indicated. f, Left – FLAG-immunoprecipitates (IP) 
from lysates of HEK293T cells expressing FLAG-tagged full-length STING (FL), NTD (a.a. 
1–140), and CTD (a.a. 140–379) were immunoblotted for detection of STIM1. Right – 
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Purified recombinant GST-fused indicated fragments of STIM1 incubated with lysates of 
HEK293T cells expressing FLAG-tagged, FL, NTD or CTD of STING were immunoblotted 
with anti-FLAG antibody. Immunoblots in panels b, c, and f are representative of four 
independent experiments. *p < 0.005 (unpaired/two-tailed t test - d).
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Figure 5. STIM1 inhibits STING trafficking to the ER-Golgi intermediate compartment.
a, Representative confocal microscopy images of WT or Stim1−/− MEFs stably expressing 
STING-GFP under resting conditions (top two panels) or 4 h after HSV-1 infection (bottom 
3 panels) and stained for endogenous p58 (ERGIC). Scale bars, 10 µm. Bar graph shows 
quantification of indicated number of cells showing STING translocation to the ERGIC 
under resting conditions or after infection with HSV-1 for indicated times. Data are derived 
from two independent experiments. b, Representative live cell epifluorescence images of 
WT (top) or Stim1−/− (bottom) MEFs after treatment with 1 µM 2’, 3’-cGAMP for the 
indicated times showing translocation of STING-GFP into the ERGIC (left). Line graph on 
the right shows normalized rate of translocation of STING in WT (9 cells) and Stim1−/− (11 
cells) MEFs from two independent experiments. Scale bar, 10 µm. c, Reporter assays for 
Ifnb1 promoter activity in HEK293T cells transfected with STING and increasing amounts 
of full length STIM1 or its indicated fragments, 6 hours after stimulation with 2’, 3’ cGAMP 
(top) or poly(I:C) (below). Data show representative triplicate from two independent 
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experiments. *p < 0.005, **p < 0.0005 Chi square test (a) and one-way ANOVA (c); N.S. – 
not significant.
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Figure 6. Ablation of STIM1 enhances host defense towards DNA viruses and HIV by priming 
type I IFN responses.
a, qPCR analysis of Ifnb1 and GFP transcripts in uninfected or HSV-1-GFP-infected (MOI 
0.1, 24 h) WT or Stim1−/− MEFs. Data show pooled technical replicates from two 
independent experiments. b, qPCR analysis of GFP and indicated viral mRNAs in MHV-68-
GFP-infected (MOI 0.2, 24 h) WT or Stim1−/− MEFs. Data show pooled technical replicates 
from three independent experiments. c, Representative immunoblots showing expression of 
phospho-IRF3 (P-IRF3), total IRF3, and 𝛽-actin from untreated or HSV-1-infected (MOI 
5.0) WT or Stim1−/− MEFs for indicated time points. d, qPCR analysis of Ifnb1 and Il6 
mRNA in untreated or HSV-1-GFP-infected (indicated MOI, 24 h) WT or Stim1−/− 
BMDMs. Data shows representative triplicate from two independent experiments. e, Top 
two panels show representative GFP images in HSV-1-GFP-infected (MOI 10, 24 h) WT, 
(left) and STIM1−/− (right) THP-1 cells. Below: qPCR analysis of IFNB1 and GFP 
transcripts from the same cells. Scale bars, 10 µm. Data shows representative triplicate from 
two independent experiments. f, Representative flow plots showing frequency of HIV-GFP-
infected WT (left) or two different STIM1−/− (right two panels) THP1 cell lines (MOI 2.0, 
24 h). Bar graph shows averaged frequency of HIV-GFP-positive indicated THP1 cell lines 
in the presence or absence of HIV reverse transcriptase inhibitor azidothymidine (AZT, 5 
µM) from four independent experiments. Immunoblots in panel c and epifluorescence 
images in panel e are representative of three and two independent experiments respectively. 
*p < 0.005 and **p < 0.0005 [Two-way ANOVA – a (left panel), d, e (right panel), f; 
unpaired/two-tailed t test – a (right panel), b; One-way ANOVA – e (left panel)].
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Figure 7. STIM1 deficiency enhances host defense against HSV-1 infection in vivo.
a, Kinetics of survival (top) and body weight changes (bottom) of indicated numbers of 
control (Stim1fl/fl) and STIM1-deficient (Stim1fl/flLyz2-cre) mice (6–7-week old) after 
intravenous injection with HSV-1 (1 × 107 PFU per mouse). b, Kinetics of survival (top) and 
body weight changes (bottom) of indicated numbers of control (Orai1fl/fl) and Orai1-
deficient (Orai1fl/flLyz2-cre) mice after intravenous injection with HSV-1 (1 × 107 PFU per 
mouse). Mice that lost >20% body weight were euthanized. c, Virus load in control 
(Stim1fl/fl) and STIM1-deficient (Stim1fl/flLyz2-cre) mouse brains 3 days after intravenous 
injection with HSV-1. d, ELISA analyses of the indicated cytokines from the sera of control 
(Stim1fl/fl) and Stim1-deficient (Stim1fl/fl Lyz2-cre) mice after intravenous injection with 
HSV-1 for indicated times. Data in panels a and b are pooled from two independent 
experiments. Panels c and d show mean +/− s.e.m. from indicated number of animals (each 
symbol represents data from individual animal). *p < 0.05, **p < 0.005, ***p < 0.0005 
(unpaired/two-tailed t test).
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